Proton Pump Inhibitors and COVID-19: Confusing Status Quo

Xiu-He Lv^{1

2}, Zi-Jing Wang^{1

2}, Jin-Lin Yang^{1

2}

Affiliations

¹ Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Sichuan, China.
² Sichuan University-Oxford University Huaxi Gastrointestinal Cancer Centre, Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Sichuan, China .

Comment

Xiu-He Lv et al. Am J Gastroenterol. 2021.

. 2021 Oct 1;116(10):2153.

doi: 10.14309/ajg.0000000000001407.

Xiu-He Lv^{1

2}, Zi-Jing Wang^{1

2}, Jin-Lin Yang^{1

2}

¹ Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Sichuan, China.
² Sichuan University-Oxford University Huaxi Gastrointestinal Cancer Centre, Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Sichuan, China .

No abstract available

Comment on

Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
Liu JJ, Sloan ME, Owings AH, Figgins E, Gauthier J, Gharaibeh R, Robinson T, Williams H, Sindel CB, Backus F, Ayyalasomayajula K, Parker A, Senitko M, Abraham GE 3rd, Claggett B, Horwitz BH, Jobin C, Adelman RM, Diamond G, Glover SC. Liu JJ, et al. Am J Gastroenterol. 2021 Aug 1;116(8):1638-1645. doi: 10.14309/ajg.0000000000001311. Am J Gastroenterol. 2021. PMID: 34047305

1. Liu JJ, Sloan ME, Owings AH, et al. Increased ACE2 levels and mortality risk of patients with COVID-19 on proton pump inhibitor therapy. Am J Gastroenterol 2021;116(8):1638–45.
1. Etminan M, Nazemipour M, Candidate MS, et al. Potential biases in studies of acid-suppressing drugs and COVID-19 infection. Gastroenterology 2021;160:1443–6.
1. Ray A, Sharma S, Sadasivam B. The potential therapeutic role of proton pump inhibitors in COVID-19: Hypotheses based on existing evidences. Drug Res 2020;70:484–8.
1. Charpiat B, Bleyzac N, Tod M. Proton pump inhibitors are risk factors for viral infections: Even for COVID-19? Clin Drug Investig 2020;40:897–9.